IDE clinical trial for artificial cervical disc completes enrollment
Synergy Spine Solutions has enrolled the last patient in its investigational device exemption (IDE) clinical trial. The 1-Level Synergy Disc …
ASCO 2023: Precigen reports positive early data for CAR-T therapy
New early data suggests Precigen Therapeutics’s CAR-T therapy PRGN-3005 could decrease tumour burden in advanced ovarian cancer. In Phase I data …
Synlogic begins Phase III trial of SYNB1934 for phenylketonuria
US-based biotechnology firm Synlogic has begun a Phase III trial of SYNB1934 for the treatment of phenylketonuria (PKU), a rare …
FogPharma doses first patient in colorectal cancer drug trial
US-based biopharmaceutical company FogPharma has dosed the first patient in its first-in-human Phase I/II clinical trial of FOG-001, a TCF-blocking …
Imbria completes patient enrolment in trial of nHCM therapy
US-based pharmaceutical company Imbria Pharmaceuticals has finished enrolling patients in its IMPROVE-HCM Phase II clinical trial of ninerafaxstat for non-obstructive …
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
ANeuroTech receives FDA approval for Phase IIIb MDD drug trial
The US Food and Drug Administration (FDA) has given clearance to ANeuroTech’s investigational new drug (IND) application, allowing the company …
EyePoint completes patient enrolment in study of NPDR therapy
US-based pharmaceutical company EyePoint Pharmaceuticals has finished enrolling patients in its Phase II PAVIA clinical trial of EYP-1901 for moderate …
Bellerophon’s study of fILD therapy fails to meet primary endpoint
US-based biotechnology firm Bellerophon Therapeutics has reported that its Phase III REBUILD clinical trial of INOpulse for the treatment of …
ASCO 2023: AstraZeneca’s PD-1/TIGIT shows promise in checkpoint-exposed NSCLC
Lung cancer is the second most common cancer globally, with non-small cell lung cancer (NSCLC) being the most common lung …
Akero’s NASH candidate and Ozempic reduce liver fat in Phase IIb cohort
New Phase IIb data suggests a combination therapy of Akero Therapeutics’s efruxifermin and Novo Nordisk’s Ozempic (semaglutide) can reduce liver …
ASCO 2023: Janssen present positive follow-up data for first in line therapy for lung cancer
Janssen Pharmaceuticals has presented long-term results from its CHRYSALIS study, which showed the combination of Rybrevant (amivantamab-vmjw) and lazertinib, was …
ASCO 2023: Janssen reports positive results for Talquetamab in Multiple myeloma
Johnson & Johnson (J&J) has reported results from its Phase I studies investigating talquetamab as a monotherapy and in combination …
ASCO 2023: Research backs chemo-only approach for some rectal cancer patients
Results unveiled at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting indicate that some patients with locally advanced …
Servier’s Phase III INDIGO trial of vorasidenib meets endpoints
Servier has reported that the Phase III INDIGO trial of vorasidenib in patients with recurrent or residual grade 2 isocitrate …
AstraZeneca reports positive results from ADAURA Phase III trial
AstraZeneca has reported positive results from the ADAURA Phase III trial of Tagrisso (osimertinib) in the adjuvant treatment of patients …